Innere Medizin (Heidelberg, Germany)最新文献_第3页

[Acute abdominal pain with surprising etiology-rare complication of a common disease]. [病因出人意料的急性腹痛--常见病的罕见并发症]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2024-10-24 DOI: 10.1007/s00108-024-01804-1

Katharina Grotemeyer, Roxana Motronea, Jörn M Schattenberg

引用次数: 0

[The effects of environmental stressors on cardiovascular health]. [环境压力对心血管健康的影响]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2024-12-30 DOI: 10.1007/s00108-024-01823-y

Thomas Münzel, Marin Kuntic, Paul Stamm, Jos Lelieveld, Andreas Daiber

{"title":"[The effects of environmental stressors on cardiovascular health].","authors":"Thomas Münzel, Marin Kuntic, Paul Stamm, Jos Lelieveld, Andreas Daiber","doi":"10.1007/s00108-024-01823-y","DOIUrl":"10.1007/s00108-024-01823-y","url":null,"abstract":"Noncommunicable diseases (NCDs) are responsible for the premature deaths of more than 38 million people each year, making them the leading cause of the global burden of disease, accounting for 70% of global mortality. The majority of these deaths are caused by cardiovascular diseases. The risk of NCDs is closely related to exposure to environmental stressors such as air pollution, noise pollution, artificial light at night, and climate change, including extreme heat, sandstorms, and wildfires. In addition to the traditional risk factors for cardiovascular diseases such as diabetes, high blood pressure, smoking, hypercholesterolemia and genetic predisposition, there is increasing evidence that physicochemical factors in the environment significantly contribute to the high NCD numbers. In addition, urbanization is related to the accumulation and intensification of these stressors. This expert review will summarize the epidemiology and pathophysiology of environmental stressors with a focus on cardiovascular NCDs. In addition, solutions and measures to mitigate the effects of environmental risks, especially concerning cardiovascular diseases, will be discussed.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"373-384"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Nivolumab and ipilimumab in patients with microsatellite instability-high metastatic colorectal cancer]. [Nivolumab和ipilimumab在微卫星不稳定性-高转移性结直肠癌患者中的应用]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-31 DOI: 10.1007/s00108-025-01876-7

Martha Kirstein, Sirka Nitschmann, Jens Marquardt

引用次数: 0

[Obesity as a chronic disease]. [肥胖是一种慢性疾病]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-26 DOI: 10.1007/s00108-025-01883-8

Pia Roser, Jens Aberle

引用次数: 0

[Purple urine bag syndrome]. [紫尿袋综合征]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-12 DOI: 10.1007/s00108-025-01882-9

Marco Franzoi, Florian Strasser, Hans Peter Gröchenig

引用次数: 0

[Beta-blockers in patients with preserved or mildly reduced ejection fraction after myocardial infarction]. [β受体阻滞剂在心肌梗死后射血分数保留或轻度降低患者中的应用]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-11 DOI: 10.1007/s00108-025-01878-5

Welf-Axel Geller, Johann Bauersachs, Sirka Nitschmann

引用次数: 0

[A rare differential diagnosis of fever of unknown origin]. 【不明原因发热的罕见鉴别诊断】。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-10 DOI: 10.1007/s00108-025-01864-x

Sabrina Welland, Linus Risser, René Abu Isneineh

引用次数: 0

[Target organ connective tissue: the variability of systemic fibrosis]. [靶器官结缔组织：系统性纤维化的变异性]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-07 DOI: 10.1007/s00108-025-01868-7

Nils Schulz, Philipp Klemm, Ulf Müller-Ladner

{"title":"[Target organ connective tissue: the variability of systemic fibrosis].","authors":"Nils Schulz, Philipp Klemm, Ulf Müller-Ladner","doi":"10.1007/s00108-025-01868-7","DOIUrl":"https://doi.org/10.1007/s00108-025-01868-7","url":null,"abstract":"The group of systemic fibrosing connective tissue diseases is remarkably diverse, comprising a wide spectrum of distinct entities. Central to their pathogenesis is the fibroblast, which, when activated by exogenous or endogenous triggers, can pathologically overproduce components of the extracellular matrix or exhibit uncontrolled proliferation. Systemic sclerosis, recognized as the prototype of systemic fibrosing diseases, belongs to the connective tissue diseases. Despite considerable advancements in the understanding of its pathogenesis, diagnosis, and treatment over recent years, systemic sclerosis remains one of the most fatal conditions among inflammatory rheumatic diseases. Its hallmark features include vasculopathy, systemic fibrosis, and autoimmunity, with common organ involvement affecting the skin, lungs, heart, gastrointestinal tract, kidneys, and musculoskeletal system. Therapeutic strategies focus on improving perfusion, controlling inflammation, and implementing antifibrotic measures. Key differential diagnoses include eosinophilic fasciitis, mixed connective tissue disease, and other overlap syndromes, which often require immunomodulatory treatment. Innovative developments in the field suggest a potential paradigm shift in the treatment of inflammatory rheumatic diseases, with cell-based therapies like CD19-depleting chimeric antigen receptor (CAR) T cell therapy showing promising early outcomes. Other systemic fibrosing diseases include scleromyxedema and scleroedema adultorum Buschke, both of which belong to the mucinoses and contribute further to the complexity of this disease group.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Fibrotic diseases in the gastrointestinal tract : Liver fibrosis and more]. [胃肠道纤维化疾病：肝纤维化等]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-03 DOI: 10.1007/s00108-025-01869-6

Elke Roeb

{"title":"[Fibrotic diseases in the gastrointestinal tract : Liver fibrosis and more].","authors":"Elke Roeb","doi":"10.1007/s00108-025-01869-6","DOIUrl":"https://doi.org/10.1007/s00108-025-01869-6","url":null,"abstract":"Chronic liver damage, such as metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis B or C, cholestatic hepatitis (PBC, PSC), toxic damage (alcohol) or genetic alterations (hemochromatosis, Wilson's disease, etc.) usually cause a chronic inflammatory response in liver cells or bile duct epithelial cells. In the long term this chronic inflammatory response can lead to scarring of the liver, a condition known as fibrosis. The development of liver fibrosis is largely independent of the causative agent, although the pattern of initial fibrosis (periportal, pericentral or sinusoidal) can vary. Untreated and progressive fibrosis can sometimes lead to complete architectural deconstruction and deposition of connective tissue in the liver, intestines and other parenchymal organs, with a gradual loss of function. In the end stage of liver cirrhosis, portal hypertension, encephalopathy, bleeding or carcinomas, e.g., hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (iCCCa), can occur. Intestinal fibrosis is one of the most devastating complications of Crohn's disease. With novel and consistent therapeutic interventions, fibrotic processes can be stopped and reversed. New research technologies have substantially improved our knowledge of liver fibrogenesis and intestinal fibrosis. The focus of this review article is on MASLD and Crohn's disease, chronic inflammatory diseases of the liver and intestines with increasing prevalence and a major impact on the general population. The current principles and potential possibilities of preventive and therapeutic antifibrotic interventions are illustrated.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Endovascular therapy of aorto-iliac occlusive disease]. 主动脉-髂闭塞性疾病的血管内治疗。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-03-01 Epub Date: 2025-02-14 DOI: 10.1007/s00108-025-01854-z

Thomas Zeller

{"title":"[Endovascular therapy of aorto-iliac occlusive disease].","authors":"Thomas Zeller","doi":"10.1007/s00108-025-01854-z","DOIUrl":"10.1007/s00108-025-01854-z","url":null,"abstract":"Background: Arterial occlusive disease of the central arteries involving the abdominal aorta and iliac arteries leads to multiple symptoms such as intermittent claudication, including of the gluteus muscle, and erectile dysfunction.Objectives: A description of the indications, technique and clinical outcomes of the endovascular therapy of aorto-iliac artery occlusive disease.Results: Due to new endovascular techniques and improved stents and stent grafts developed over the last two decades, the endovascular therapy of aorto-iliac obstructions has become the standard method for the treatment of intermittent claudication in experienced centers. Open surgical bypass revascularisation is mainly indicated after a failed endovascular attempt or in the case of unfavourable anatomy for endovascular therapy, including flush occlusions distal to the renal artery origins. A less frequently used revascularisation technique, the hybrid revascularisation, combines open surgical thromboendarterectomy of the common femoral artery and stent implantation of the ipsilateral iliac artery or aorta. Obstructions of the internal iliac artery resulting in, among other things, erectile dysfunction and hip claudication are ever more frequently treated with either drug-eluting stents or balloons.Conclusion: In the case of appropriate operator experience and suitable anatomy, endovascular therapy has become the first-line revascularisation strategy for aorto-iliac occlusive disease involving the internal iliac artery.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"249-257"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0